Effects of metformin on weight loss and metabolic control in obese patients with schizophrenia and schizoaffective disorder: a randomized, double-blind, controlled clinical trial
Authors
Abstract:
Abstract Objective: The effect of metformin on weight changes and some metabolic parameters in patients with schizophrenia and schizoaffective disorder was investigated in this study. Methods: This study, performed during 2018-2019, was a randomized, double-blind, controlled clinical trial. A total of 66 obese patients (BMI≥27) with schizophrenia and schizoaffective disorder, hospitalized in the departments of Razi Psychiatric Hospital, after completing the informed consent form, entered the study and randomly divided into intervention and control groups. The patients received metformin or placebo for 12 weeks. The dose of metformin was gradually increased, and, in case of patient’s tolerance, was prescribed up to 500 mg twice daily. During the study, all patients received their previous therapies. The variables included BMI, weight, waist circumference, lipid profile and fasting blood glucose, which were studied at the beginning of the study and at weeks 4, 8, and 12. Data were analyzed using a post hoc test by SPSS software. Results: The results showed a significant decrease in weight (3.5 kg) and BMI (1.30) at the end of the week 12, and there was a significant reduction in waist circumference (5.9 cm) at the end of the week 8, compared to the placebo group (P <0.05). Moreover, metformin had no significant effect on fasting blood glucose and lipid profile in comparison with the placebo group. Conclusion: Based on the findings of this study, metformin by reducing the weight, waist circumference, and BMI can have a significant role in decreasing the complications of obesity and metabolic disorders in patients with schizophrenia and schizoaffective disorder; Therefore, given that the complications of metformin are low and transient, it can be recommended as a safe and tolerable drug in obese patients having schizoaffective disorder and schizophrenia. Keywords: Schizophrenia, schizoaffective disorder, obesity, metformin, antipsychotics.
similar resources
Effect of Memantine on Positive Sign in Patients with Schizophrenia and Schizoaffective Disorders: A Randomized Double Blind Placebo Controlled Trial
Background and purpose: Memantine is a medication used to treat moderate to severe Alzheimer’s disease. Memantine targeting the glutamatergic system specifically N-Methyl-D-Aspartate offer a novel approach in treatment of psychiatric disorders such as schizophrenia and schizoaffective disorder. The purpose of this study was to evaluate the efficacy and safety of memantine in combination with an...
full textEffect of acupressure on constipation in patients undergoing hemodialysis: A randomized double-blind controlled clinical trial
Objective: Constipation is one of the most common digestive problems in patients undergoing hemodialysis. It has a negative effect on quality of life in these patients. As routine treatments are not effective in this regard, complementary therapies may help to overcome this condition. This study aimed to investigate the effect of acupressure on constipation in patients undergoing hemodialysis. ...
full textEffect of Statin Treatment on COVID-19 Patients’ Outcomes: A Randomized Double-blind Controlled Clinical Trial
Background: Statins may be protective against viral infection and have been suggested for the treatment of coronavirus disease 2019 (COVID-19). Objective: In this study, we aimed to evaluate the effect of atorvastatin on COVID-19 patients. Methods: Our study is a randomized double-blind controlled clinical trial that constitutes a population of COVID-19 patients admitted to Bu-Ali Sina Hospi...
full textCardiovascular and Renal Effects of Hibiscus Sabdariffa Linnaeus. in Patients with Diabetic Nephropathy: A Randomized, Double-Blind, Controlled Trial
Background: Hibiscus sabdariffa linnaeus (HSL) is a tropical plant with a high content of anthocyanin, traditionally found to have beneficial biological activities. This randomized, double-blind, placebo-controlled, and parallel trial was conducted to assess some renal and cardiovascular effects of supplementation with HSL in patients with diabetic nephropathy. Methods: The study protocol was c...
full textLow Dose Celecoxib Combined with Clozapine for Treatment of Schizophrenia: A Double Blind Randomized Clinical Trial
Introduction: Higher levels of pro-inflammatory cytokines in schizophrenia have suggested that dysfunctions of the immune system may play a role in this disabling condition. The current study was performed to discover if low dose celecoxib combined with clozapine may improve symptoms of schizophrenia or not. Methods:<span...
full textEfficacy and safety of bupropion in quality of life of cancer patients, a randomized double blind placebo controlled clinical trial
Background and purpose: Decreasing the quality of life in cancer patients is an essential factor that influences their lives during the process of treatment and after that. A lot of studies have been done to evaluate the efficacy of medical agents on quality of life. In this study, we evaluate the efficacy of Bupropion as an antidepressant agent in quality of life of cancer patients. Materials...
full textMy Resources
Journal title
volume 17 issue 4
pages 0- 0
publication date 2019-12
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023